California-Based Opal Therapeutics Receives $1.25M Investment

Opal Therapeutics, a San Francisco, CA-based provider of a patient-derived organoid platform that enables therapeutic and diagnostic development in women’s gynecological health, has received a $1.25M investment from the National Science Foundation (NSF).

The company plans to use the funding to expand its laboratory infrastructure, scale organoid manufacturing, strengthen imaging and inflammation assays and build larger internal datasets.

Funding Snapshot

About Opal Therapeutics

Founded in 2023, by Morgan Stanton, Opal Therapeutics is a San Francisco based biotechnology company focused on developing treatments and diagnostics for chronic conditions affecting womens reproductive health. By screening therapeutic candidates early in human uterine tissue, Opal is unlocking the next generation of treatments for women.

Read More:Bernat Olle Co-Founded Vedanta Biosciences Scores $60M in Funding

The company uses patient derived uterine organoids and cells to generate human relevant biological and drug-response data. Its platform is designed to address limitations in traditional animal models, particularly when studying diseases that may behave differently in humans.

Core offerings include:

• Patient derived uterine organoids
• Human disease models
• Drug response testing
• Imaging and inflammation assays
• Biological datasets

Core Technologies / Products / Services